Mankind Pharma Limited (MANKIND) Share Price

NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE634S01028

₹2,351.00-5.50 (-0.23%)

Key metrics

Market Cap
₹97,323 Cr
P/E Ratio
47.75
EPS
49.35
Book Value
401.16
P/B Ratio
5.94
ROE
11.55%
ROCE
12.4%
Debt / Equity
0.38
Net Margin
13.4%
Revenue Growth
16.96%
Profit Growth
-3.92%
Dividend Yield
0.08%
52W High
₹2,674.00
52W Low
₹1,909.70
Market Cap Band
large cap
Face Value
1

Ratios computed from the annual results period ending 2026-03-31.

About Mankind Pharma Limited

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Headquarters
New Delhi, India
Employees
20,451
Promoter Holding
75.4%

The full Mankind Pharma Limited analysis

Create a free account to open the complete MANKIND deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.

  • 10-year financialsIncome statement, balance sheet and cash flow, year by year.
  • Valuation & fair valueFair-value estimates, quality scores and a value grade.
  • Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
  • Shareholding historyPromoter, FII, DII and public holdings across every quarter.
  • Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
  • Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.